Why Diabetic Wounds Won't Heal and What New Therapies Are Changing That

Diabetic foot ulcers represent one of medicine's most persistent failures: despite decades of research, up to 34% of the world's 536 million diabetes patients will develop a DFU in their lifetime, recurrence reaches 65% within five years of healing, and infected ulcers carry a 17% amputation rate and 15% one-year mortality. Annual management costs exceed $35,000 per patient. This review from Wang, Gu, and colleagues at Shanghai Jiao Tong University synthesizes the full mechanistic landscape of DFU pathogenesis and maps it onto both established and emerging therapeutic strategies.

At the metabolic core of the problem is chronic hyperglycemia, which saturates normal glycolysis and diverts glucose into the polyol pathway. Aldose reductase converts glucose to sorbitol, depleting NADPH and overproducing NADH. Hexokinase-2 gains aberrant stability at high glucose concentrations, generating excess glucose-6-phosphate that displaces HK-2 from mitochondria, causing membrane hyperpolarization and reactive oxygen species accumulation. Meanwhile, fructose-6-phosphate feeds the hexosamine pathway, producing excessive O-GlcNAcylation that masks AKT phosphorylation sites, directly reinforcing insulin resistance. Inhibiting O-GlcNAcyltransferase was shown in preclinical studies to accelerate wound closure, identifying it as a therapeutic target.

Advanced glycation end products (AGEs) compound the damage by cross-linking extracellular matrix proteins and activating RAGE receptors, which trigger NF-κB, MAPK, JNK, and PKC cascades. These pathways simultaneously promote proinflammatory cytokine transcription and phosphorylate IRS-1 on serine residues, further blocking insulin signaling. The review also details how saturated fatty acid accumulation and PUFA deficiency drive lipotoxicity, impair synthesis of pro-resolving lipid mediators (resolvins, protectins), and sustain neutrophil extracellular trap formation — all hallmarks of the DFU microenvironment.

At the cellular level, diabetic macrophages are locked in a pro-inflammatory M1 state, failing to transition to pro-resolving M2 phenotypes during the proliferative phase. Fibroblasts show impaired proliferation, reduced collagen synthesis, and attenuated contractility under high-glucose conditions, while keratinocyte migration is blunted by reduced galectin-7 secondary to elevated O-GlcNAcylation. Angiogenesis is compromised through AR-mediated suppression of RUNX2, a key transcriptional regulator of vascular repair. Diabetic peripheral neuropathy and peripheral artery disease compound these cellular failures by eliminating protective sensation and reducing tissue perfusion, creating the permissive environment for ulceration.

The review critically evaluates animal models, noting that current STZ-induced rodent and db/db mouse models fail to replicate human DFU complexity, particularly the neuropathic and vascular comorbidity burden. Among emerging therapies, mesenchymal stem cell-derived exosomes receive extensive attention for their ability to modulate macrophage polarization and deliver pro-angiogenic cargo. Bioengineered skin substitutes, growth factor delivery systems, gene therapy targeting HIF-1α and VEGF, and antimicrobial photodynamic therapy are highlighted as promising translational candidates. The authors note that validating these interventions in models that better recapitulate human DFU biology is the critical next step toward reducing amputations and mortality at scale.